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Dedicated to the late Caesar Milstein, who was instrumental for this studyAbstract At present, the conformation-dependent monoclonal
antibodies (mAb) provide the only information on folding of tau
in the core PHF. Monoclonal antibody MN423 recognizes all
and only those Alzheimer’s disease (AD) core paired helical
ﬁlaments (PHFs) subunits, which terminate at Glu391. Using
recombinant analogs of the core PHF subunit corresponding to
tau residues s297–391, we found that the C-terminal pentapep-
tide 387DHGAE391 represented only one component of the
structure recognized by mAb 423. Therefore, deletion mutants
of the core subunit were generated to identify assembled parts of
this conformational structure. We localized two spatially close
components in the region 306–325 (306VQIVYK311 and
321KCGSL325) contributing to formation of the structure iden-
tiﬁed by mAb 423. Thus, the spatial proximity of three subunit
segments 306VQIVYK311, 321KCGSL325 and 387DHGAE391 rep-
resents constraints for intramolecular folding of the core PHF
subunit. Since PHF represents a compelling drug target in AD,
structural knowledge presented could contribute to structure-
based drug design.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Paired helical ﬁlament1. Introduction
The abnormal hyperphosphorylation and polymerization of
the tau protein into paired helical ﬁlaments (PHFs) is a
seminal event in the pathogenesis of Alzheimer’s disease
(AD). It is broadly accepted that tau dysfunction causes
neurodegeneration, with the formation of tau ﬁlaments in AD
[1–4]. While all the available data suggest that normal tau has
no discrete structure, the presence of highly ordered tau as-* Corresponding authors. Fax: +1-718-494-1080 (K. Iqbal),
+421-2-54774276 (M. Novak).
E-mail addresses: iqbalk@worldnet.att.net (K. Iqbal),
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Abbreviations: AD, Alzheimer’s disease; ECL, enhanced chemilumi-
nescence; ELISA, enzyme linked immunosorbent assay; mAb, mono-
clonal antibody; NMR, nuclear magnetic resonance; PBS, phosphate
buﬀered saline; PHF, paired helical ﬁlaments; SDS–PAGE, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2004.04.098semblies (e.g., PHF) in AD indicates that, in the disease state,
tau can and does adopt a diﬀerent conformation. Proteolytic
cleavage dissected Alzheimer’s PHF into two structurally
distinct parts: protease-sensitive fuzzy coat and a protease-
resistant PHF (termed core PHF), which retained its char-
acteristic morphological features [5]. This implicated that the
structure of core PHF should be of fundamental importance
in the process of tau polymerization. Considerable eﬀort has
been aimed at understanding the structure of the pathological
tau in PHF [6]. Inherent physicochemical properties of tau
preclude conformational analysis of PHF by X-ray crystal-
lography or NMR spectroscopy. In such situation, well-
characterized antibodies provide invaluable tool to assess the
protein folding if they recognize conformational epitope. The
generation of conformation-dependent antibodies provides
evidence that tau, a natively unfolded protein [7], is capable
of undergoing conformational changes upon polymeriza-
tion into highly ordered ﬁlaments during the course of AD
[8–12].
Monoclonal antibody 423 recognizes a three dimensional
structure which is speciﬁc for tau assembled into PHF in
brains of patients with AD but is not present in normal brains
[13]. Since previous studies demonstrated that the epitope of
423 is conformational [8,11], phosphorylation independent
[8,13] and core PHF speciﬁc [8,14–16], its full molecular
mapping could signiﬁcantly contribute to unraveling the
molecular basis of PHF formation in AD. Doing this, present
work represents ﬁrst structural insight into folding of core
PHF subunit.2. Materials and methods
2.1. Preparation, expression and puriﬁcation of core PHF subunit dGAE
and its deletion mutants
The preparation of cDNA coding for core PHF subunit dGAE (res-
idues s297–391) was described elsewhere [16]. The numbering of amino
acids is that of the isoform human s40 containing 441 residues [17]. For
primary structure of dGAE subunit, see Fig. 1. dGAE mutants with
amino-terminal deletions (s306–391, s316–391, s321–391 and s326–391)
(see Fig. 3A) were derived from cDNA dGAE by PCR using speciﬁc
primers. dGAE-mutants with internal deletions [(dGAEDI, dGAEDII,
dGAEDIII, dGAED(I + II), and dGAED(I + III)] (see Fig. 4A) were
derived from cDNA dGAE by inverse PCR with inverted primers
ﬂanking the deleting sequence. All DNA constructs were cloned in
pET17b vector (Novagen) through NdeI–EcoRI restriction sites. In-
tegrity of each construct was veriﬁed by DNA sequence analysis (ABI
Prism 377 DNA Sequencer, Perkin–Elmer).ation of European Biochemical Societies.
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Fig. 1. Structure diagram of core PHF subunit dGAE and its amino-
acid sequence. Numbering follows that of the human tau40 [17]. I1,
I2 – aminoterminal inserts, R1–4, R0 – repeat regions.
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bacterial lysates (without acid and boiling pretreatment) by one step
cation exchange chromatography [18]. The purity of proteins analyzed
by SDS–PAGE was more than 90% (data not shown). The protein
concentration was determined by scanning densitometry of Coomassie
Brilliant Blue stained polyacrylamide gels (data not shown) using
program UnScanItGel (SilkScientiﬁc Corp., USA).
Synthetic oligopeptides corresponding to the sequences of tau
387DHGAE391 and 382AKAKTDHGAE391 (purity >95%) were pur-
chased from Interactiva, Germany.
2.2. MAb and competitive immunoassay
Monoclonal antibodies (mAb) 423 was raised against an enriched
preparation of PHFs [14]. Antibody was puriﬁed from ascitic ﬂuid and
conjugated with horseradish peroxidase (KemEnTec, Denmark).
The competitive ELISA against solid phase was performed in ﬂexible
microtitration plates (Becton Dickinson, Cat. No. 3912, USA) as fol-
lows: The competiton plate was coated with 50 ll/well of dGAE (18.8
nM) in phosphate buﬀered saline (PBS), pH 7.2, and then incubated
overnight at 4 C. On the separate plate, serially diluted competitors in
PBS were mixed with peroxidase-labeled mAb 423 (0.4 mg/ml). 50 ll
per well of the competitor-antibody mixtures was transferred in trip-
licate to the blocked and washed competition plate and incubated at 37
C for 35 min. Bound labeled mAb 423 was detected with ortho-
phenylenediamine (Sigma) and plates were read at 492 nm in an iEMS
Reader (Labsystems, Finland).
Competition curves for each peptide were ﬁtted using four parameter
logistic algorithm and computed and plotted using GraphPad Prism
version 3.02 for Windows (GraphPad Software, USA). The values of
EC50 (the eﬀective concentration of half-maximal competition) were
calculated, which reﬂect the antibody aﬃnity [19]. Ratio between EC50
of respective peptide and EC50 of dGAE was designated as r. It indi-
cates relative decrease (r-fold) in aﬃnity of peptide in relation to full
aﬃnity of dGAE. All quantitative experimental results shown are from
measurement done in triplicate. Error bars in ﬁgures represent stan-
dard error of the mean.
2.3. Immunoelectron microscopy
Immunoelectron microscopy of pronase-treated PHFs with mAb
423 was carried out as described [5,6]. Human AD brain tissue was
obtained from Slovak Brain Bank (Bratislava).
2.4. SDS–PAGE and western blotting
The core PHF subunit (dGAE) and its deletion mutants were ana-
lyzed on SDS–PAGE and Western blot as described previously [18].
ECL developed Western blot was digitalized with LAS3000 CCD
imaging system (Fujiﬁlm, Japan). Densitometric data analysis and
relative quantiﬁcation of Western blot record were performed by
AIDA Biopackage (Raytest, Germany) as described [18].Fig. 2. Contribution of C-terminal component of core PHF subunit to
mAb 423 aﬃnity. Figure shows competition between tau C-terminal
peptides and core subunit dGAE for binding with mAb 423. Compe-
tition curves reﬂect diﬀerences in mAb 423 aﬃnity to respective sub-
unit-derived peptides. Tetrapeptide GAEI represents a negative
control lacking measurable reactivity. EC50 value was used as a mea-
sure of aﬃnity; r (ratio between EC50 of respective peptide and EC50 of
dGAE) indicates relative decrease in aﬃnity of mAb 423 to peptide in
relation to the full reactivity of subunit dGAE.3. Results and discussion
While the exact molecular structure of both the normal and
AD pathological conformation of tau remains to be eluci-
dated, it has been shown that both conformations do exist as
discrete molecular entities [8]. Intramolecular interactions inthe core PHF subunits are largely unknown. Therefore, we
exploited conformation-dependent mAb 423 as an eﬀective
tool for the identiﬁcation of spatially proximal segments in
core PHF subunits which deﬁne constraints for folding into
mAb 423-speciﬁc antigenic structure. Analogical strategy for
determination of tau folding during early PHF formation was
recently employed in studies with conformational-dependent
mAbs Alz-50, MC-1, TG-3 and Tau-66 [9,10,12]. These au-
thors, however, used only qualitative immunochemical meth-
ods (Western blot, ELISA) for folding analysis. In contrast, we
employed sensitive quantitative competitive ELISA, which
allows precise determination of the contribution of individual
polypeptide segments to the folding of the core PHF tau. For
this study, recombinant core PHF subunit analog termed
dGAE corresponding to tau residues s297–391 (Fig. 1) was
used as a representative core subunit.
3.1. Aﬃnity of the mAb 423 to the C-terminal regions of core
PHF subunit
Previous study of the core PHF subunits identiﬁed the C-
terminal glutamic acid at position 391 as crucial for adopting
the local speciﬁc conformation recognized by mAb 423 [16].
The removal or addition of a single amino acid to the C-ter-
minus (Glu391) abolishes the reactivity with mAb 423, sug-
gesting that it has an absolute requirement for a free carboxy
terminus. However, this result did not provide an answer to the
question whether this C-terminal residue has only structural
role or it is also involved in direct interaction with the antibody.
To outline this, synthetic peptides were derived from C-termi-
nal region of dGAE and then were assessed for binding with
mAb 423 in competitive ELISA using dGAE subunit as a
competitor (Fig. 2). Aﬃnity comparisons showed that C-ter-
minal pentapeptide 387DHGAE391 of the core subunit exhibited
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Fig. 3. Identiﬁcation of N-terminal segment contributing to core
subunit conformation. (A) Diagram of N-terminal deletion mutants
derived from core subunit dGAE. The region 306–325 important for
conformation of core subunit dGAE is colored blue. Position of C-
terminal pentapeptide is shown in green. (B) Figure shows competition
between N-terminal deletion mutants of dGAE and full-length dGAE
for binding with mAb 423. Competition curves reﬂect diﬀerences be-
tween subunit mutants in reactivity with mAb 423. EC50 value was
used as a measure of aﬃnity; r (ratio between EC50 of respective
mutants and EC50 of dGAE) indicates relative decrease in aﬃnity of
mAb 423 to peptide in relation to the full reactivity of subunit dGAE.
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directly reacted with structural probe mAb 423. Nevertheless,
the aﬃnity of the pentapeptide was 700 times lower than that
of the complete subunit dGAE (Fig. 2). Further N-terminal
extension of immunoreactive pentapeptide to decapeptide
382AKAKTDHGAE391 or even further upstream until residue
326 (fragment s326–391) did not increase the aﬃnity. This
suggested that region 326–386 was not directly involved in the
formation of core PHF subunit structure recognized by mAb
423. Taken together, these ﬁndings suggested that the sequence
387DHGAE391 represented whole C-terminal component of the
complex structure deﬁned by mAb 423.
3.2. Contribution of the N-terminal part of the core PHF
subunit to intramolecular folding
Structural analysis of subunit dGAE implicated, in addition
to the C-terminal pentapeptide, contribution of N-terminal
region (297–325) to the folding of core PHF subunit. In order
to identify individual segments essential for this folding, we
prepared N-terminal deletion mutants of subunit dGAE.
Four dGAE deletion mutants with diﬀerent N-termini were
constructed and their reactivities with mAb 423 assayed
(Fig. 3A). It has been shown [8,16] that variability between six
core PHF subunits is restricted to the region corresponding in
dGAE to the ﬁrst nine N-terminal residues (297–305). The
mutant (s306–391) lacking this region showed equal immu-
noreactivity to that of dGAE (Fig. 3B). This ﬁnding showed
that residues 297–305 were not essential for assuming 423-
speciﬁc conformation of core PHF. However, it also indicated
that the most signiﬁcant N-terminal contribution to the core
PHF-folding had to be delivered by residues 306–325.
Further N-terminal deletions of core subunit dGAE beyond
Ser305 gradually decreased the immunoreactivity of resulting
mutants. The mutants s316–391 (D 297–315) and s321–391 (D
297–320) showed 4.3- and 37-fold decrease in aﬃnity, respec-
tively, when compared to that of full-length core PHF subunit
dGAE. Nevertheless, the reactivities of these mutants were still
substantially higher than the reactivity of subunit C-terminal
pentapeptide 387DHGAE391. However, further removal of
subsequent ﬁve residues downstream (D 321–325) yielded the
subunit fragment s326–391 with weaker binding capacity than
that exhibited by pentapeptide 387DHGAE391 (Fig. 3B). To-
gether, these data suggested that region 321KCGSL325 could
represent complementary component participating in the for-
mation of folded subunit structure. To test directly whether the
sequence 321KCGSL325 was crucial for immunoreactivity and
thus to the conformation of the core PHF subunit, we engi-
neered dGAE mutants with internal deletion of individual
segments designated as domain I (306VQIVYK311), domain II
(314DLSKVTS320) and domain III (321KCGSL325) (Fig. 4A).
Surprisingly, deleting domain III (dGAEDIII) led to decrease
in aﬃnity only about 8-fold, indicating thus signiﬁcant con-
tribution of either domain I or II to the folding constraints of
core PHF subunit (Fig. 4B). Deletion of domain II (dGAEDII)
had similar low impact on aﬃnity (about 6-fold reduction) as
deletion of domain III. The major destabilizing eﬀect on sub-
unit structure resulted from removing the domain I (dGAEDI),
which caused 25-fold decrease in aﬃnity similar to the level of
fragment s321–391 (Fig. 3). It showed that sequence
306VQIVYK311 had an important contribution in adopting
conformational characteristic of core PHF subunit. Never-
theless, none of the examined domains (I, II, III) aloneexhibited suﬃcient capacity to reduce the aﬃnity to that of
subunit C terminal pentapeptide 387DHGAE391. These results
suggested a local fold encompassed in region 306–325 that
could represent the assembled N-terminal component of the
conformation recognized by mAb 423 in core PHF subunit.
Crucial role in this fold appeared to be assigned to domain I.
To prove this possibility, we engineered subunit dGAE mu-
tants which had domain I deleted simultaneously with either
domain II [dGAED(I + II)] or domain III [dGAED(I + III)].
The decrease in reactivity (23-fold) of the double mutant
dGAED(I + II) was close to that of the mutant lacking the
domain I (dGAEDI) (Fig. 4). In contrast, deletion of both
domains I and III [dGAED(I + III)] resulted in dramatic de-
crease in aﬃnity (650-fold) to the level exhibited by core sub-
unit C-terminal pentapeptide 387DHGAE391. These ﬁndings
raised the possibility that the N-terminal component of mAb
423-speciﬁc conformation was formed in core subunit by a
local fold comprising domains I and III.
3.3. Domain arrangement in folded PHF core
Considering the limited size of antigen-binding region of an
antibody (1000 A2 on average), the C-terminus and N-terminal
region 306–325 of core subunit had to be in close proximity to
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Fig. 4. Role of domains in segment 306–325 contributing to the N-
terminal fold of core subunit structure. (A) Diagram of internal dele-
tion mutants derived from subunit dGAE. Positions of domains I, II,
III and C-terminal pentapeptide are shown. (B) Competition between
deletion mutants of dGAE and full-length dGAE for binding with
mAb 423 is shown. Competition curves reﬂect diﬀerences between
subunit mutants in reactivity with mAb 423. EC50 value was used as a
measure of aﬃnity; r (ratio between EC50 of respective mutants and
EC50 of dGAE) indicates relative decrease in aﬃnity of mAb 423 to
peptide in relation to the full reactivity of dGAE.
Fig. 5. Quantitative Western blot analysis of the core PHF subunit and
its mutants gives results complementary to those obtained by ELISA.
(A) 100 ng of individual tau proteins were loaded onto 10–20% gra-
dient SDS–PAGE. Following electroblotting, membrane was stained
with peroxidase-labeled mAb 423. (B) Comparison of reactivity in
competitive ELISA (expressed as reciprocal EC50 values) and Western
blot reactivity (corrected for molecular weight of individual proteins).
All data are normalized to 100% values of dGAE core PHF subunit.
Fig. 6. Folding of subunit core PHF into b-sheet conformation. (A)
Immunoelectron microscopy of Pronase-resistant core PHF shows
typical immunogold decoration with mAb 423. Pronase-resistant core
was isolated and immunodecorated as described [5,6]. PHFs were
isolated from AD brain, stage VI, according to Braak [20]. (B) Primary
structure of core PHF subunit (dGAE) with individual segments es-
sential for polypeptide folding (red – based on EC50 values) and with
regions of predicted b-strands is shown. (C) Core PHF subunit adopts
b-sheet structure. Proposed core structure is based on predicted b-
strand propensities and experimental EC50 values of core PHF speciﬁc
mAb 423.
R. Skrabana et al. / FEBS Letters 568 (2004) 178–182 181each other, provided that core PHF tau adopts a folded
structure. Based on this assumption, formation of local N-
terminal fold in core PHF subunit could be mediated by direct
interaction of domains I and III with C-terminal residues in
vicinity or within the pentapeptide 387DHGAE391. The C-ter-
minal component is essential for folding of subunit dGAE,
whereas the N-terminal component is only able to contribute
when the C-terminal component is engaged. The absolute re-
quirement for glycine at position 389 may indicate an impor-
tance of local C-terminal ﬂexibility of subunit for adopting a
core PHF conformation [11]. Therefore, the spatial proximity
of three subunit segments 306VQIVYK311, 321KCGSL325 and
387DHGAE391 represents constraints for intramolecular fold-
ing of the core PHF subunit. The immunoreactivity of tau
deletion mutants with mAb 423 was analyzed also in Western
blotting and compared with data from competitive ELISA
(Fig. 5). Results from Western blot quantiﬁcation were con-
sistent with data from ELISA experiments.
It is interesting that polypeptide segments from the over-
lapping parts of tau molecules, namely residues 312–322 and
305–314, were identiﬁed as important contributors to the im-
munoreactivity of conformational antibodies MC-1 and Tau-
66 [10,12]. However, these mAbs have been used for deﬁnition
182 R. Skrabana et al. / FEBS Letters 568 (2004) 178–182of an overall fold of tau molecule before its assembly into
PHF. In contrast, the 423 was raised against already folded
core PHF and therefore could disclose tau conformation re-
sponsible for PHF stability. Taking together, requirement for
the third microtubule-binding region of tau is common de-
nominator for immunoreactivity of conformational antibodies
MC-1, Tau-66 and 423. This indicates the fundamental role of
this region in both PHF genesis and its stabilization. The
constraints that determine dGAE subunit folding appear to be
characteristic of an assembled conﬁguration of core PHF tau
in AD. Based on these ﬁndings, we present a model depicting
folding of the core PHF subunit, dGAE, in which we propose
the formation of b-sheet (Fig. 6) with domain I and/or III
acting as an intramolecular zipper for b-sheet formation. Such
conformation of dGAE could represent binding interface for
assembly of core unit (dGAE) into core PHF. The work rep-
resents ﬁrst information on subunit core PHF folding and
would contribute to deciphering the molecular mechanism of
PHF assembly.
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